[Identification of a metabolic immune regulator in the host that protects against influenzal pneumonia]

A Cezard; A Guillon; M Si-Tahar

doi:10.1016/j.rmr.2021.05.003

[Identification of a metabolic immune regulator in the host that protects against influenzal pneumonia]

Rev Mal Respir. 2021 Jun;38(6):567-571. doi: 10.1016/j.rmr.2021.05.003. Epub 2021 May 20.

[Article in French]

Authors

A Cezard¹, A Guillon², M Si-Tahar³

Affiliations

¹ Inserm, Centre d'Étude des Pathologies Respiratoires (CEPR), UMR 1100, Tours, France; Université de Tours, Tours, France. Electronic address: [email protected].
² Inserm, Centre d'Étude des Pathologies Respiratoires (CEPR), UMR 1100, Tours, France; Université de Tours, Tours, France; CHRU de Tours, Service de Médecine Intensive Réanimation, Tours, France.
³ Inserm, Centre d'Étude des Pathologies Respiratoires (CEPR), UMR 1100, Tours, France; Université de Tours, Tours, France.

PMID: 34024644
DOI: 10.1016/j.rmr.2021.05.003

Abstract

The 'flu, caused mostly by influenza A and B viruses, represents a major public health issue. Despite vaccines and antiviral drugs, the therapeutic arsenal is still suboptimal. Recently, several studies have reported the antiviral and anti-inflammatory properties of several host metabolites. Now, we show that a metabolite (called here "C2") has a potent anti-influenza activity by blocking the viral replication and by limiting the downstream pro-inflammatory signalling. These results pave the way for the development of innovative metabolic therapy against influenzal pneumonia.

Keywords: Antiviral therapy; Immunometabolism; Immunométabolisme; Influenza; Thérapie anti-grippale; Virus.

Publication types

Review

MeSH terms

Antiviral Agents / therapeutic use
Humans
Influenza Vaccines* / therapeutic use
Influenza, Human* / drug therapy
Influenza, Human* / prevention & control
Pneumonia* / drug therapy
Pneumonia* / prevention & control
Virus Replication

Substances

Antiviral Agents
Influenza Vaccines